Methods of treating acute pancreatitis using IL-22 fc fusion proteins

CPC - классификация

AA6A61A61KA61K3A61K38A61K38/A61K38/0A61K38/00A61K38/2A61K38/20A61K4A61K47A61K47/A61K47/3A61K47/38A61PA61P1A61P1/A61P1/0A61P1/04A61P13A61P13/A61P13/1A61P13/12A61P17A61P17/A61P17/0A61P17/02A61P3A61P3/A61P3/0A61P3/00A61P3/04A61P3/06A61P3/1A61P3/10A61P31A61P31/A61P31/0A61P31/04A61P39A61P39/A61P39/0A61P39/02A61P4A61P43A61P43/A61P43/0A61P43/00A61P9A61P9/A61P9/0A61P9/00A61P9/1A61P9/10A61P9/12CC0C07C07KC07K1C07K14C07K14/C07K14/5C07K14/54C07K16C07K16/C07K16/2C07K16/28C07K16/286C07K16/2866C07K2C07K23C07K231C07K2319C07K2319/C07K2319/3C07K2319/30

IPC - классификация

AA6A61A61KA61K3A61K38A61K38/A61K38/0A61K38/00A61K38/2A61K38/20A61K4A61K47A61K47/A61K47/3A61K47/38A61PA61P1A61P1/A61P1/0A61P1/04A61P1/1A61P1/16A61P4A61P43A61P43/A61P43/0A61P43/00CC0C07C07KC07K1C07K14C07K14/C07K14/5C07K14/54C07K16C07K16/C07K16/2C07K16/28

Цитирование НПИ

435/69.52
Adams et al., “Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for mu, alpha, gamma 1, gamma 2a, and gamma 3 chains,” Biochemistry. 19(12):2711-9 (1980).
Andoh et al., “Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts,” Gastroenterology. 129(3):969-84 (2005).
Apelqvist et al., “What is the most effective way to reduce incidence of amputation in the diabetic foot,” Diabetes Metab Res Rev. 16 Suppl 1:S75-83 (2000) (abstract only).
Apelqvist, “What is the value of treating a diabetic foot wound?” (Consensus Development Conference on Diabetic Foot Wound Care: Apr. 7-8, 1999, Boston, Massachusetts. American Diabetes Association) Diabetes Care. 22(8):1354-60 (1999).
Aplin et al., “Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids,” CRC Crit Rev Biochem. 10(4):259-306 (1981).
Barcia et al., “Triglyceride-rich lipoproteins as agents of innate immunity,” Clin Infect Dis. 41 Suppl 7:S498-503 (2005).
Beck et al., “Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies,” mAbs. 3(5):415-6 (2011) (3 pages).
Beck et al., “Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins,” Curr Pharm Biotechnol. 9(6):482-501 (2008).
Bradley, Chapter 5: Production and analysis of chimaeric mice. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. E. J. Robertson, ed. IRL, Oxford. 113-151 (1987).
Brand et al., “IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration,” Am J Physiol Gastrointest Liver Physiol. 290(4):G827-38 (2006).
Brandi et al., “MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection,” J Exp Med. 204(8):1891-900 (2007).
Brubaker et al., “Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age,” J Immunol. 190(4):1746-57 (2013).
Bry et al., “Critical role of T cell-dependent serum antibody, but not the gut-associated lymphoid tissue, for surviving acute mucosal infection with Citrobacter rodentium, an attaching and effacing pathogen,” J Immunol. 172(1):433-41 (2004).
Brüggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” J Exp Med. 166(5):1351-61 (1987).
Buford, Wound Healing and Pressure Sores, HealingWell.com, published on Oct. 24, 2001 (5 pages).
Cani et al., “Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice,” Diabetes. 57(6):1470-81 (2008).
Cani et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” Diabetes. 56(7)1761-72 (2007).
Carter et al., “Improved oligonucleotide site-directed mutagenesis using M13 vectors,” Nucleic Acids Res. 13(12):4431-43 (1985).
Cash et al., “Refolding, purification, and characterization of human and murine RegIII proteins expressed in Escherichia coli,” available in PMC Sep. 8, 2009, published in final edited form as: Protein Expr Purif. 48(1):151-9 (2006).
Cash et al., “Symbiotic bacteria direct expression of an intestinal bactericidal lectin,” available in PMC Jul. 28, 2009, published in final edited form as: Science. 313(5790):1126-30 (2006).
Chang et al., “Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase,” Nature. 275(5681):617-24 (1978).
Charlton, “Expression and isolation of recombinant antibody fragments in E. coli,” Methods Mol Biol. 248:245-54 (2004).
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol. 196(4):901-17 (1987).
Clackson et al., “Making antibody fragments using phage display libraries,” Nature. 352(6336):624-8 (1991).
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci U S A. 95(2):652-6 (1998).
Communication Pursuant to Article 94(3) for European Patent Application No. 18158054.9, dated Sep. 24, 2019 (4 pages).
Communication pursuant to Article 94(3) EPC for European Patent Application No. 18158054.9, dated Jul. 24, 2020 (5 pages).
Couffinhal et al., “Mouse model of angiogenesis,” Am J Pathol. 152(6):1667-79 (1998).
Cox et al., “Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice,” Mucosal Immunol. 5(1):99-109 (2012).
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood. 103(7):2738-43 (2004).
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood. 101(3):1045-52 (2003).
Creighton, Proteins: Structures and Molecular Principles. New York, NY; W.H. Freeman and Company, 70-87 (1984).
Cwirla et al., “Peptides on phage: a vast library of peptides for identifying ligands,” Proc Natl Acad Sci U S A. 87(16):6378-82 (1990).
Dargaville et al., “Sensors and imaging for wound healing: a review,” Biosens Bioelectron. 41:30-42 (2013).
Database accession No. AZL47299, created Oct. 3, 2019 (1 page).
De Boer et al., “The tac promoter: a functional hybrid derived from the trp and lac promoters,” Proc Natl Acad Sci U S A. 80(1):21-5 (1983).
Decision of Rejection for Japanese Patent Application No. 2016-503181, dated Nov. 13, 2018 (8 pages).
Decision of the Intellectual Property Office for Taiwanese Patent Application No. 103109979, dated Jul. 25, 2019 (10 pages).
Dolby et al., “Cloning and partial nucleotide sequence of human immunoglobulin mu chain cDNA from B cells and mouse-human hybridomas,” Proc Natl Acad Sci U S A. 77(10):6027-31 (1980).
Domschke et al., “Preface,” Ann N Y Acad Sci. 1072:xi (2006).
Dumoutier et al., “Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22,” J Immunol. 166(12):7090-5 (2001).
Duncan et al., “The binding site for C1q on IgG,” Nature. 332(6166):738-40 (1988).
Eckmann, “Animal models of inflammatory bowel disease: lessons from enteric infections,” Ann N Y Acad Sci. 1072:28-38 (2006).
Edge et al., “Deglycosylation of glycoproteins by trifluoromethanesulfonic acid,” Anal Biochem. 118(1):131-7 (1981).
English Translation of Office Action for Chinese Patent Application No. 201480015176.2, dated Aug. 17, 2018 (9 pages).
English Translation of Office Action for Taiwanese Patent Application No. 103109979, dated Oct. 25, 2018 (4 pages).
English Translation of Search Report and Written Opinion for Brazilian Patent Application No. BR112015023140-3, dated Oct. 22, 2019 (4 pages).
Erwin et al. Lipopolysaccharide binding protein in acute pancreatitis. Crit Care Med. Jan. 2000;28(1):104-9.
Evan et al., “Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product,” Mol Cell Biol. 5(12):3610-6 (1985).
Examination Report No. 1 for Australian Patent Application No. 2018223004, dated Apr. 2, 2019 (6 pages).
Examination Report No. 1 for Australian Patent Application No. 2020205284, dated Mar. 8, 2021 (4 pages).
Examination Report for Gulf Cooperation Council Patent Application No. 2014-26755, dated Aug. 2, 2018 (6 pages).
Examination Report for Gulf Cooperation Council Patent Application No. 2014-36963, dated Dec. 20, 2020 (4 pages).
Examination Report for Gulf Cooperation Council Patent Application No. 2014-36963, dated Jun. 24, 2019 (4 pages).
Examination Report for Gulf Cooperation Council Patent Application No. GC 2014-26755, dated Mar. 12, 2019 (4 pages).
Examination Report for Indian Patent Application No. 5523/CHENP/2015, dated Feb. 17, 2020 (7 pages).
Examination Report for Indonesian Patent Application No. P00201505642, received Mar. 11, 2018 (4 pages).
Examination Report for Singaporean Patent Application No. 11201507429T, dated Jul. 26, 2018 (6 pages).
Falkner et al., “Expression of mouse immunoglobulin genes in monkey cells,” Nature. 298(5871):286-8 (1982).
Field et al., “Purification of a RAS-responsive adenylyl cyclase complex from Saccharomyces cerevisiae by use of an epitope addition method,” Mol Cell Biol. 8(5):2159-65 (1988).
Fisher et al., “mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic,” Cancer Biol Ther. 2(4 Suppl 1):S23-37 (2003).
Ganz et al., “Defensins: Natural Peptide Antibiotics of Human Neutrophils,” J Clin Invest. 76(4):1427-35 (1985).
Ganz, “Defensins and host defense,” Science. 286(5439):420-1 (1999).
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods. 202(2):163-71 (1997).
Gerngross, “Advances in the production of human therapeutic proteins in yeasts and filamentous fungi,” Nat Biotechnol. 22(11):1409-14 (2004).
Gething et al., “Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene,” Nature. 293(5834):620-5 (1981).
Geysen et al., Synthetic Peptides as Antigens. John Wiley & Sons, 130-149 (1986).
Geysen et al., “Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein,” Proc Natl Acad Sci U S A. 82(1):178-82 (1985).
Geysen et al., “Strategies for epitope analysis using peptide synthesis,” J Immunol Methods. 102(2):259-74 (1987).
Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,” Proc Natl Acad Sci U S A. 81(13):3998-4002 (1984).
Ghosal et al., “Hydroxypropyl methylcellulose in drug delivery,” Der Pharmica Sinica. 2(2):152-68 (2011).
Ghoshal et al., “Chylomicrons promote intestinal absorption of lipopolysaccharides,” J Lipid Res. 50(1):90-7 (2009).
Gironella et al., “Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease,” Gut. 54(9):1244-53 (2005) (11 pages).
Gironella et al., “Experimental acute pancreatitis in PAP/HIP knock-out mice,” Gut. 56(8):1091-7 (2007).
Goeddel et al., “Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone,” Nature. 281(5732):544-8 (1979).
Goeddel et al., “Synthesis of human fibroblast interferon by E. coli,” Nucleic Acids Res. 8(18):4057-74 (1980).
Gough et al., “Molecular cloning of seven mouse immunoglobulin kappa chain messenger ribonucleic acids,” Biochemistry. 19(12):2702-10 (1980).
Graham et al., “A new technique for the assay of infectivity of human adenovirus 5 DNA,” Virology. 52(2):456-67 (1973).
Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5,” J Gen Virol. 36(1):59-72 (1977).
Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors,” J Immunol. 117(2):587-93 (1976).
Hamako et al., “Comparative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian species,” Comp Biochem Physiol B. 106(4):949-54 (1993).
Hansson et al., “The immune system in atherosclerosis,” Nat Immunol. 12(3):204-12 (2011).
Hansson, “Inflammation, atherosclerosis, and coronary artery disease,” N Engl J Med. 352(16):1685-95 (2005).
Happel et al., “Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae,” J Exp Med. 202(6):761-9 (2005).
Hellström et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci U S A. 83(18):7059-63 (1986).
Hellström et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci U S A. 82(5):1499-502 (1985).
Hess et al., “Cooperation of glycolytic enzymes,” Adv Enzyme Regul. 7:149-67 (1969).
Higgins et al., “Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease,” Infect Immun. 67(6):3031-9 (1999).
Hitzeman et al., “Isolation and characterization of the yeast 3-phosphoglycerokinase gene (PGK) by an immunological screening technique,” J Biol Chem. 255(24):12073-80 (1980).
Holland et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,” Biochemistry. 17(23):4900-7 (1978).
Hopp et al., “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification,” Nat Biotechnol. 6:1204-10 (1988).
Hristodorov et al., “With or without sugar? (A)glycosylation of therapeutic antibodies,” Mol Biotechnol. 54(3):1056-68 (2012).
Hsiao et al., “High-frequency transformation of yeast by plasmids containing the cloned yeast ARG4 gene,” Proc Natl Acad Sci U S A. 76(8):3829-33 (1979).
Idusogie et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc,” J Immunol. 164(8):4178-84 (2000).
International Search Report for International Patent Application No. PCT/US2014/029652, dated Jan. 20, 2015.
Iovanna et al., “Messenger RNA sequence and expression of rat pancreatitis-associated protein, a lectin-related protein overexpressed during acute experimental pancreatitis,” J Biol Chem. 266(36):24664-9 (1991).
Isner et al., “Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease,” Hum Gene Ther. 7(8):959-88 (1996).
Jiang et al., “IL-22 is related to development of human colon cancer by activation of STAT3,” BMC Cancer. 13:59 (2013).
Jones, “Proteinase mutants of Saccharomyces cerevisiae,” Genetics. 85(1):23-33 (1977).
Jurjus et al., “Animal models of inflammatory bowel disease,” J Pharmacol Toxicol Methods. 50(2):81-92 (2004).
Kaistha et al., “Homology modeling of phosphoryl thymidine kinase of enterohemorrhagic Escherichia coli OH: 157,” Bioinformation. 3(6):240-3 (2009).
Kanda et al., “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC,” Biotechnol Bioeng. 94(4):680-8 (2006).
Kang et al., “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,” Proc Natl Acad Sci U S A. 88(10):4363-6 (1991).
Kawada et al., “Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease,” World J Gastroenterol. 13(42):5581-93 (2007).
Keilbaugh et al., “Activation of RegIIIbeta/gamma and interferon gamma expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut,” Gut. 54(5):623-9 (2005) (8 pages).
Keown et al., “Methods for introducing DNA into mammalian cells,” Methods Enzymol. 185:527-37 (1990).
Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor,” Eur J Immunol. 24(10):2429-34 (1994).
Kindt et al., Kuby Immunology Sixth Edition. New York: W.H. Freeman and Company, 91 (2007).
Kingsman et al., “Replication in Saccharomyces cerevisiae of plasmid pBR313 carrying DNA from the yeast trp1 region,” Gene. 7(2):141-52 (1979).
Kobayashi et al., “A novel core fucose-specific lectin from the mushroom Pholiota squarrosa,” J Biol Chem. 287(41):33973-82 (2012).
Kreis et al., “Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells,” PLoS One. 2(12):e1300 (2007) (15 pages).
Kreymborg et al., “IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis,” J Immunol. 179(12):8098-104 (2007).
Kumar et al., “IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration,” J Cancer. 4(1):57-65 (2013).
Lakso et al., “Targeted oncogene activation by site-specific recombination in transgenic mice,” Proc Natl Acad Sci U S A. 89(14):6232-6 (1992).
Lavitrano et al., “Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice,” Cell. 57(5):717-23 (1989).
Lazarus et al., “Definitions and guidelines for assessment of wounds and evaluation of healing,” Arch Dermatol. 130(4):489-93 (1994).
Levillayer et al., “Interleukin 22 is a candidate gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases,” Genetics. 176(3):1835-44 (2007).
Li et al., “Optimization of humanized IgGs in glycoengineered Pichia pastoris,” Nat Biotechnol. 24(2):210-5 (2006).
Li et al., “Targeted mutation of the DNA methyltransferase gene results in embryonic lethality,” Cell. 69(6):915-26 (1992).
Liang et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides,” J Exp Med. 203(10):2271-9 (2006).
Lo, “Transformation by iontophoretic microinjection of DNA: multiple integrations without tandem insertions,” Mol Cell Biol. 3(10):1803-14 (1983).
Lowman et al., “Selecting high-affinity binding proteins by monovalent phage display,” Biochemistry. 30(45):10832-8 (1991).
Lutz-Freyermuth et al., “Quantitative determination that one of two potential RNA-binding domains of the A protein component of the U1 small nuclear ribonucleoprotein complex binds with high affinity to stem-loop II of U1 RNA,” Proc Natl Acad Sci U S A. 87(16):6393-7 (1990).
Lécart et al., “IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells,” Int Immunol. 14(11):1351-6 (2002).
Maaser et al., “Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies,” Infect Immun. 72(6):3315-24 (2004).
Manco et al., “Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk,” Endocr Rev. 31(6):817-44 (2010).
Mangan et al., “Transforming growth factor-beta induces development of the T(H)17 lineage,” Nature. 441(7090):231-4 (2006).
Mansour et al., “Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes,” Nature. 336(6197):348-52 (1988).
Mantei et al., “Rabbit beta-globin mRNA production in mouse L cells transformed with cloned rabbit beta-globin chromosomal DNA,” Nature. 281(5726):40-6 (1979).
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J Mol Biol. 222(3):581-97 (1991).
Martin et al., “GAP domains responsible for ras p21-dependent inhibition of muscarinic atrial K+ channel currents,” Science. 255(5041):192-4 (1992).
Mather, “Establishment and characterization of two distinct mouse testicular epithelial cell lines,” Biol Reprod. 23(1):243-52 (1980).
Mayer et al. Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis. Br J Surg. Feb. 2002;89(2):163-71.
McGee et al., “IL-22 promotes fibroblast-mediated wound repair in the skin,” J Invest Dermatol. 133(5):1321-9 (2013).
Merrifield, “Solid phase peptide synthesis: the synthesis of a tetrapeptide,” J Am Chem Soc. 85:2149-54 (1963).
Missé et al., “IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction,” J Immunol. 178(1):407-15 (2007).
Mizoguchi, “Healing of intestinal inflammation by IL-22,” Inflamm Bowel Dis. 18(9):1777-84 (2012).
Morrison et al., “Transfer and expression of immunoglobulin genes,” Annu Rev Immunol. 2:239-56 (1984).
Moucadel et al., “Cdx1 promotes cellular growth of epithelial intestinal cells through induction of the secretory protein PAP I,” Eur J Cell Biol. 80(2):156-63 (2001).
Mundy et al., “Citrobacter rodentium of mice and man,” Cell Microbiol. 7(12):1697-706 (2005).
NCBI GenBank Accession No. AAH67509.1, dated Jul. 15, 2006, accessed Mar. 29, 2018 (2 pages).
NCBI GenBank Accession No. AY358890.1, dated Oct. 3, 2003, accessed Mar. 29, 2018 (2 pages).
NCBI GenBank Accession No. NP_940850, dated Jun. 26, 2017, accessed Apr. 10, 2018 (2 pages).
Niwa et al., “IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides,” J Immunol Methods. 306(1-2):151-60 (2005).
Non-Final Rejection for U.S. Appl. No. 16/128,008, dated Dec. 22, 2020 (231 pages).
Non-Final Rejection for U.S. Appl. No. 16/196,823, dated Dec. 24, 2020 (68 pages).
Non-Final Rejection for U.S. Appl. No. 16/196,936, dated Dec. 24, 2020 (60 pages).
Notice of Preliminary Rejection for Korean Patent Application No. 1020157028479, dated Jul. 9, 2020 (9 pages).
Notice of Reasons for Rejection for Japanese Patent Application No. 2016-503181, dated May 8, 2018 (10 pages).
Notice of Reasons for Rejection for Japanese Patent Application No. 2018-185857, dated Apr. 14, 2020 (8 pages).
Notice of Reasons for Rejection for Japanese Patent Application No. 2018-185857, dated Aug. 13, 2019 (4 pages).
Notification for Vietnamese Patent Application No. 1-2015-03407, dated Aug. 28, 2020 (4 pages).
Notification of Defects in Israeli Patent Application No. 240561, dated Jan. 30, 2019 (10 pages).
Office Action for Canadian Patent Application No. 2,903,587, dated Jan. 10, 2020 (4 pages).
Office Action for Canadian Patent Application No. 2,903,587, dated May 27, 2019 (4 pages).
Office Action for Mexican Patent Application No. MX/a/2015/011146, dated Nov. 26, 2018 (11 pages).
Office Action for U.S. Appl. No. 14/214,161, dated Aug. 9, 2016 (13 pages).
Office Action for U.S. Appl. No. 14/214,161, dated Jul. 20, 2017 (15 pages).
Office Action for U.S. Appl. No. 15/217,790, dated Jan. 30, 2017 (11 pages).
Office Action for U.S. Appl. No. 15/454,662, dated Nov. 30, 2018 (17 pages).
Office Action for U.S. Appl. No. 15/801,867, dated May 9, 2019 (10 pages).
Ogawa et al., “Identification of genes involved in mucosal defense and inflammation associated with normal enteric bacteria,” Am J Physiol Gastrointest Liver Physiol. 279(3):G492-9 (2000).
Ogawa et al., “Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model,” Inflamm Bowel Dis. 9(3):162-70 (2003).
Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa,” J Mol Biol. 336(5):1239-49 (2004).
Orelle et al. Human Pancreatitis-associated Protein . J. Clin. Invest., vol. 90, Dec. 1992, 2284-2291.
Ota et al., “IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium,” Nat Immunol. 12(10):941-8 (2011).
Ouyang et al., “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annu Rev Immunol. 29:71-109 (2011).
Paborsky et al., “Mammalian cell transient expression of tissue factor for the production of antigen,” Protein Eng. 3(6):547-53 (1990).
Pastorelli et al., “Emerging drugs for the treatment of ulcerative colitis,” Expert Opin Emerg Drugs. 14(3):505-21 (2009).
Patent Examination Report No. 1 for New Zealand Application No. 711095, dated Aug. 3, 2020 (4 pages).
Patent Examination Report No. 1 for New Zealand Application No. 751498, dated Aug. 3, 2020 (6 pages).
Patent Examination Report No. 1 for New Zealand Application No. 751499, dated Aug. 3, 2020 (6 pages).
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol. 18(12):1759-69 (2006).
Pickert et al., “STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing,” J Exp Med. 206(7):1465-72 (2009).
Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ‘roulette,’” J Immunol. 150(3):880-7 (1993).
Powell-Braxton et al., “A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet,” Nat Med. 4(8):934-8 (1998).
Preliminary Rejection for Brazilian Patent Application No. BR112015023140-3, dated Aug. 24, 2020 (11 pages).
Pull et al., “Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury,” Proc Natl Acad Sci U S A. 102(1):99-104 (2005).
Ravetch et al., “Fc receptors,” Annu Rev Immunol. 9:457-92 (1991).
Rejection Decision for Chinese Patent Application No. 201480015176.2, dated Mar. 9, 2021 (9 pages).
Renauld, “Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators,” Nat Rev Immunol. 3(8):667-76 (2003).
Rice et al., “Regulated expression of an immunoglobulin kappa gene introduced into a mouse lymphoid cell line,” Proc Natl Acad Sci U S A. 79(24):7862-5 (1982).
Ripka et al., “Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose,” Arch Biochem Biophys. 249(2):533-45 (1986).
Ross, “Atherosclerosis is an inflammatory disease,” Am Heart J. 138(5 Pt 2):S419-20 (1999).
Sa et al., “The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis,” J Immunol. 178(4):2229-40 (2007).
Sabat et al., “IL-22 and IL-17: An Overview,” IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. V. Quesniaux et al., 11-35 (2013).
Schoofs et al., “Epitopes of an influenza viral peptide recognized by antibody at single amino acid resolution,” J Immunol. 140(2):611-6 (1988).
Search Report for Eurasian Patent Application No. 202090582, dated Nov. 9, 2020 (5 pages).
Search Report for Singaporean Patent Application No. 11201507429T, dated Aug. 3, 2016 (4 pages).
Search Report for Taiwanese Patent Application No. 103109979, dated Oct. 23, 2018 (2 pages).
Second Office Action for Chinese Patent Application No. 201480015176.2, dated May 29, 2020 (14 pages).
Shaw et al., “A general method for the transfer of cloned genes to plant cells,” Gene. 23(3):315-30 (1983).
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem. 276(9):6591-604 (2001).
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,” J Biol Chem. 277(30):26733-40 (2002).
Shoji-Hosaka et al., “Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides,” J Biochem. 140(6):777-83 (2006).
Simmons et al., “Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma,” J Immunol. 168(4):1804-12 (2002).
Singer et al., “Cutaneous wound healing,” N Engl J Med. 341(10):738-46 (1999).
Skinner et al., “Use of the Glu-Glu-Phe C-terminal epitope for rapid purification of the catalytic domain of normal and mutant ras GTPase-activating proteins,” J Biol Chem. 266(22):14163-6 (1991).
Smith, “Surface presentation of protein epitopes using bacteriophage expression systems,” Curr Opin Biotechnol. 2(5):668-73 (1991).
Sojar et al., “A chemical method for the deglycosylation of proteins,” Arch Biochem Biophys. 259(1):52-7 (1987).
Stinchcomb et al., “Isolation and characterisation of a yeast chromosomal replicator,” Nature. 282(5734):39-43 (1979).
Substantive Examination Report for Philippines Patent Application No. 1/2015/502125, dated Oct. 2, 2019 (5 pages).
Sugimoto et al., “IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis,” J Olin Invest. 118(2):534-44 (2008).
Sugimoto et al., “Innate Cell-Targeting Therapeutic Effect of IL-22 on Experimental Colitis,” AGA Abstracts, Gastroenterology. 130(4 Suppl 2):A41 Abstract 232 (2006).
Sugimoto et al., “Local IL-22 Gene Delivery Targeting Inflamed Mucosa Induces the Rapid Attenuation with Goblet Cell Restitution,” Gastroenterology. 132(4 Suppl 2):A-153 Abstract 1012 (2007).
Sun et al. “IL-22 is involved in atherosclerosis lesions by regulated impaired proliferation ability of oxidized low density lipoprotein treated CRL-1730,” Chin J Microbiol Immunol. 32:995-9 (2012).
Ta et al., “DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice,” J Cardiovasc Pharmacol. 58(2):157-166 (2011) (18 pages).
Takeshita et al., “Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo,” Lab Invest. 75(4):487-501 (1996).
Tan et al., “MRI of the diabetic foot: differentiation of infection from neuropathic change,” Br J Radiol. 80(959):939-48 (2007).
Thomas et al., “Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells,” Cell. 51(3):503-12 (1987).
Thomas, “Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose,” Proc Natl Acad Sci U S A. 77(9):5201-5 (1980).
Thompson et al., “Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells,” Cell. 56(2):313-21 (1989).
Thotakura et al., “Enzymatic deglycosylation of glycoproteins,” Methods Enzymol. 138:350-9 (1987).
Toy et al., “Cutting edge: interleukin 17 signals through a heteromeric receptor complex,” J Immunol. 177(1):36-9 (2006).
Tschumper et al., “Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene,” Gene. 10(2):157-66 (1980).
Turnbaugh et al., “The core gut microbiome, energy balance and obesity,” J Physiol. 587(Pt 17):4153-8 (2009).
Urlaub et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc Natl Acad Sci U S A. 77(7):4216-20 (1980).
Van Solingen et al., “Fusion of yeast spheroplasts,” J Bacteriol. 130(2):946-7 (1977).
Van der Putten et al., “Efficient insertion of genes into the mouse germ line via retroviral vectors,” Proc Natl Acad Sci U S A. 82(18):6148-52 (1985).
Weber et al., “Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis,” Infect Immun. 75(4):1690-7 (2007).
Wells et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene. 34(2-3):315-23 (1985).
Wells et al., “Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin,” Phil Trans R Soc Lond A. 317:415-23 (1986).
Wolk et al., “IL-22 increases the innate immunity of tissues,” Immunity. 21(2):241-54 (2004).
Wolk et al., “IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease,” J Immunol. 178(9):5973-81 (2007).
Wolk et al., “IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis,” Eur J Immunol. 36(5):1309-23 (2006).
Wright et al., “Effect of glycosylation on antibody function: implications for genetic engineering,” Trends Biotechnol. 15(1):26-32 (1997).
Written Opinion for Singaporean Patent Application No. 11201507429T, dated Oct. 13, 2016 (8 pages).
Wu et al., “Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1,” Sci Transl Med. 3(113):113ra126 (2011).
Xavier et al., “Unravelling the pathogenesis of inflammatory bowel disease,” Nature. 448(7152):427-34 (2007).
Xie et al., “Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R,” J Biol Chem. 275(40):31335-9 (2000).
Xu et al., “A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist,” Proc Natl Acad Sci U S A. 98(17):9511-6 (2001).
Xue et al., “Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis,” Gastroenterology. 143(6):1670-80 (2012).
Yamane-Ohnuki et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity,” Biotechnol Bioeng. 87(5):614-22 (2004).
Yazaki et al., “Expression of recombinant antibodies in mammalian cell lines,” Methods Mol Biol. 248:255-68 (2004).
Zenewicz et al., “Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation,” Immunity. 27(4):647-59 (2007).
Zhao et al., “Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model,” Wound Repair Regen. 20(3):342-52 (2012).
Zheng et al., “Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens,” Nat Med. 14(3):282-9 (2008).
Zheng et al., “Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature. 445(7128):648-51 (2007).
Zoller et al., “Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA,” Nucleic Acids Res. 10(20):6487-500 (1982).